CN105769863A - 替拉那韦在抗癌症药物中的应用及抗癌症药物 - Google Patents
替拉那韦在抗癌症药物中的应用及抗癌症药物 Download PDFInfo
- Publication number
- CN105769863A CN105769863A CN201610144660.6A CN201610144660A CN105769863A CN 105769863 A CN105769863 A CN 105769863A CN 201610144660 A CN201610144660 A CN 201610144660A CN 105769863 A CN105769863 A CN 105769863A
- Authority
- CN
- China
- Prior art keywords
- tipranavir
- cell
- parts
- processes
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510151531.5A CN104784179A (zh) | 2015-04-01 | 2015-04-01 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
CN2015101515315 | 2015-04-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105769863A true CN105769863A (zh) | 2016-07-20 |
CN105769863B CN105769863B (zh) | 2018-11-27 |
Family
ID=53549684
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510151531.5A Pending CN104784179A (zh) | 2015-04-01 | 2015-04-01 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
CN201610144660.6A Active CN105769863B (zh) | 2015-04-01 | 2016-03-14 | 替拉那韦在抗癌症药物中的应用及抗癌症药物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510151531.5A Pending CN104784179A (zh) | 2015-04-01 | 2015-04-01 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN104784179A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112263578A (zh) * | 2020-11-27 | 2021-01-26 | 深圳大学 | Tipranavir在制备杀伤肿瘤干细胞和肿瘤细胞的癌症治疗药物中的用途 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101489537A (zh) * | 2006-07-19 | 2009-07-22 | 阿伯特有限及两合公司 | 药学上可接受的增溶组合物和包含其的药物剂型 |
WO2014018932A2 (en) * | 2012-07-27 | 2014-01-30 | Bunt Antonius Martinus Gustave | Effluz inhibitor compositions and methods of treatment using the same |
WO2014080251A1 (en) * | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
WO2014151535A1 (en) * | 2013-03-15 | 2014-09-25 | Bayer Healthcare Llc | Gla domains as targeting agents |
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
-
2015
- 2015-04-01 CN CN201510151531.5A patent/CN104784179A/zh active Pending
-
2016
- 2016-03-14 CN CN201610144660.6A patent/CN105769863B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101489537A (zh) * | 2006-07-19 | 2009-07-22 | 阿伯特有限及两合公司 | 药学上可接受的增溶组合物和包含其的药物剂型 |
WO2014018932A2 (en) * | 2012-07-27 | 2014-01-30 | Bunt Antonius Martinus Gustave | Effluz inhibitor compositions and methods of treatment using the same |
WO2014080251A1 (en) * | 2012-11-24 | 2014-05-30 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
WO2014151535A1 (en) * | 2013-03-15 | 2014-09-25 | Bayer Healthcare Llc | Gla domains as targeting agents |
CN104784179A (zh) * | 2015-04-01 | 2015-07-22 | 重庆理工大学 | 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112263578A (zh) * | 2020-11-27 | 2021-01-26 | 深圳大学 | Tipranavir在制备杀伤肿瘤干细胞和肿瘤细胞的癌症治疗药物中的用途 |
CN112263578B (zh) * | 2020-11-27 | 2022-02-11 | 深圳大学 | Tipranavir在制备杀伤肿瘤干细胞和肿瘤细胞的癌症治疗药物中的用途 |
WO2022111670A1 (zh) * | 2020-11-27 | 2022-06-02 | 深圳大学 | Tipranavir在制备杀伤肿瘤干细胞和肿瘤细胞的癌症治疗药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN105769863B (zh) | 2018-11-27 |
CN104784179A (zh) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guo et al. | Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE‑cadherin/EphA2/MMP9/MMP2 expression | |
Li et al. | Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells | |
WO2017162108A1 (zh) | 一种柱芳烃类复合物、其制备方法、药物组合物和用途 | |
EP3498274B1 (en) | Application of phosphodiesterase 4 inhibitor zl-n-91 in preparation of medicament for treating prostate cancer proliferation and metastasis | |
Xie et al. | Comparation of Anti‐Inflammatory and Antioxidantactivities of Curcumin, Tetrahydrocurcuminand Octahydrocurcuminin LPS‐Stimulated RAW264. 7 Macrophages | |
Jiang et al. | Chaetocin: A review of its anticancer potentials and mechanisms | |
He et al. | Cephalosporin antibiotics specifically and selectively target nasopharyngeal carcinoma through HMOX1-induced ferroptosis | |
CN102058609A (zh) | 虎杖苷在制备抗肿瘤药物中的应用 | |
WO2023092943A1 (zh) | 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用 | |
Tang et al. | Epigallocatechin gallate induces chemopreventive effects on rats with diethylnitrosamine‑induced liver cancer via inhibition of cell division cycle 25A | |
US10959977B2 (en) | Application of phosphodiesterase 4 inhibitor ZL-n-91 in preparation of medications for lung cancer proliferation and metastasis | |
CN105769846A (zh) | 一种gpr35激动剂及其应用 | |
Tang et al. | Ginsenoside 3β-O-Glc-DM (C3DM) enhances the antitumor activity of Taxol on Lewis lung cancer by targeting the interleukin-6/Jak2/STAT3 and interleukin-6/AKT signaling pathways | |
Li et al. | Proapoptotic and Growth-inhibitory Effects of Plumbagin on Human Gastric Cancer Cells Via Suppression of Signal Transducer and Activator of Transcription 3 and Protein Kinase B. | |
Tang et al. | The novel hepatoprotective mechanisms of silibinin-phospholipid complex against d-GalN/LPS-induced acute liver injury | |
CN105769863A (zh) | 替拉那韦在抗癌症药物中的应用及抗癌症药物 | |
Huang et al. | Ethyl pyruvate inhibits glioblastoma cells migration and invasion through modulation of NF-κB and ERK-mediated EMT | |
CN105476996A (zh) | 姜黄素与阿法替尼联合治疗非小细胞肺癌的用途 | |
CN102688489B (zh) | 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用 | |
CN106974908A (zh) | 含有hdac抑制剂和ire1抑制剂的药物组合物及用途 | |
WO2020087938A1 (zh) | 脾酪氨酸激酶作为肝内胆管细胞癌治疗靶点的应用 | |
CN102836151B (zh) | Brevilin A在制备JAK-STATs信号靶向抑制剂中的应用 | |
Li et al. | AAZ2 induces mitochondrial-dependent apoptosis by targeting PDK1 in gastric cancer | |
CN102441167B (zh) | 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 | |
He et al. | Comparison of anti-tumor activities and underlying mechanisms of glucuronomannan oligosaccharides and its sulfated derivatives on the hepatocarcinoma Huh7. 5 cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Lin Zhihua Inventor after: Shu Mao Inventor after: Meng Lingxin Inventor after: Ding Xuelei Inventor after: Guo Bo Inventor after: Zhu Bo Inventor after: Wang Rui Inventor after: Lin Yong Inventor after: Hu Yong Inventor after: Wang Yuanqiang Inventor before: Lin Zhihua Inventor before: Ding Xuelei Inventor before: Guo Bo Inventor before: Zhu Bo Inventor before: Wang Rui Inventor before: Lin Yong Inventor before: Hu Yong Inventor before: Wang Yuanqiang Inventor before: Shu Mao |
|
COR | Change of bibliographic data | ||
GR01 | Patent grant | ||
GR01 | Patent grant |